Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.

Published byWalter Butler Modified over 7 years ago

Similar presentations

Presentation on theme: "Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham."— Presentation transcript:

1 Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham Nagarakanti, Herbert Noack, Martina Brueckmann, Claire Litherland, Mark Jacobs, Andreas Clemens, Paul A. Reilly, Stuart J. Connolly, Salim Yusuf, and Lars Wallentin Circulation Volume 134(8):589-598 August 23, 2016 Copyright © American Heart Association, Inc. All rights reserved.

2 Efficacy and safety outcomes in patients with and without valvular heart disease (VHD) in the total RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) population (propensity-adjusted analysis). Michael D. Ezekowitz et al. Circulation. 2016;134:589-598 Copyright © American Heart Association, Inc. All rights reserved.

3 Comparison of stroke and systemic embolic events on both dabigatran doses (RE-LY [Randomized Evaluation of Long-Term Anticoagulant Therapy]), rivaroxaban (ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation]), and apixaban (ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation]) vs warfarin in patients with or without valvular heart disease (VHD). Michael D. Ezekowitz et al. Circulation. 2016;134:589-598 Copyright © American Heart Association, Inc. All rights reserved.

4 Comparison of rates of all-cause mortality on both dabigatran doses (RE-LY [Randomized Evaluation of Long-Term Anticoagulant Therapy]), rivaroxaban (ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation]), and apixaban (ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation]) vs warfarin in patients with or without valvular heart disease (VHD). Michael D. Ezekowitz et al. Circulation. 2016;134:589-598 Copyright © American Heart Association, Inc. All rights reserved.

5 Comparison of major bleeding event rates on both dabigatran doses (RE-LY [Randomized Evaluation of Long-Term Anticoagulant Therapy]), rivaroxaban (ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation]), and apixaban (ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation]) vs warfarin in patients with or without valvular heart disease (VHD). Michael D. Ezekowitz et al. Circulation. 2016;134:589-598 Copyright © American Heart Association, Inc. All rights reserved.

6 Comparison of intracranial bleeding on both dabigatran doses (RE-LY [Randomized Evaluation of Long-Term Anticoagulant Therapy]), rivaroxaban (ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation]), and apixaban (ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation]) vs warfarin in patients with or without valvular heart disease (VHD). Michael D. Ezekowitz et al. Circulation. 2016;134:589-598 Copyright © American Heart Association, Inc. All rights reserved.

7 Comparison of outcomes of patients with exclusive right-sided valvular heart disease (VHD) or mitral stenosis (presumably rheumatic) and patients without any form of VHD. CI indicates confidence interval; NOAC, novel oral anticoagulant; and SEE, systemic embolic event. Michael D. Ezekowitz et al. Circulation. 2016;134:589-598 Copyright © American Heart Association, Inc. All rights reserved.

Download ppt "Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham."

Similar presentations

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.

ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.
JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.

JOURNAL REVIEW Newer Antithrombotics in AF 1 Dr Ranjith MP Senior Resident Department of Cardiology Government Medical college Kozhikode.
Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.

Georges Ghanem MD, FESC, FACC Associate Professor, Chief of Cardiology UMC-RH/LAU-SOM Beirut, Lebanon.
Patients Are Undertreated NABOR Warfarin/Warfarin + Aspirin No Treatment Patients, % Waldo AL, et al. J Am Coll Cardiol. 2005;46:1729-1736. [3] Retrospective.

Patients Are Undertreated NABOR Warfarin/Warfarin + Aspirin No Treatment Patients, % Waldo AL, et al. J Am Coll Cardiol. 2005;46: [3] Retrospective.
Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,

Apixaban versus Aspirin in Atrial Fibrillation Patients ≥ 75 years old: An Analysis from the AVERROES Trial Kuan H Ng, Olga O Shestakovska, John W. Eikelboom,
Standard Medical Therapy TRA 40 mg + 2.5 mg/d TRA 40 mg + 2.5 mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.

Standard Medical Therapy TRA 40 mg mg/d TRA 40 mg mg/d Placebo EP:CV Death/MI/stroke/hosp for RI/urgent coronary revasc. 1  EP:CV Death/MI/stroke/hosp.
Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.

Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.
ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.

ARISTOTLE TRIAL Dr R Nyabadza GPST1 Ward 32. Structure AF, stroke and CHA 2 -DS 2 VASC Anticoagulant choices ARISTOTLE trial Cost NICE guidance and the.
Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation.

Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation.
Study by: Granger et al. NEJM, September 2011,Vol. 365. No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.

Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.

Atrial Fibrillation Stroke Prevention with Oral Anticoagulants Why is there discordance between guideline committees & specialists when the data is based.
  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target

  Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban Target
Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group 9 611 - 10/06/11.

Oral Rivaroxaban for Symptomatic Venous Thrombroenbolism Group /06/11.
Dodson Thompson, DO Northlakes Community Clinic Minong, WI.

Dodson Thompson, DO Northlakes Community Clinic Minong, WI.
UK/CVS-121035(1) | February 2013 Emerging technologies for stroke prevention in atrial fibrillation UK/CVS-121035(1) | Date of preparation: February 2013.

UK/CVS (1) | February 2013 Emerging technologies for stroke prevention in atrial fibrillation UK/CVS (1) | Date of preparation: February 2013.
Atrial Fibrillation Management Past, Present and Future

Atrial Fibrillation Management Past, Present and Future
Ashfaq Shuaib, MD Professor of Neurology and Medicine Director University of Alberta Stroke Program University of Alberta New Oral Anticoagulants in Stroke.

Ashfaq Shuaib, MD Professor of Neurology and Medicine Director University of Alberta Stroke Program University of Alberta New Oral Anticoagulants in Stroke.
Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.

Guillaume Pare MD Genetic determinants of dabigatran plasma levels and their relation to bleeding On behalf of RE-LY Genetics: Guillaume Pare MD, Niclas.
ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.

ARISTOTLE Objectives Primary: test for noninferiority of apixaban, a novel oral direct factor Xa inhibitor, versus warfarin Secondary: test for superiority.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.

Similar presentations

Ads by Google